Tracey Iraca

Medical experts offer their insights and closing remarks regarding patient feedback for MDS.

Medical experts discuss considerations and patient guidance for oral and IV HMAs.

Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.

Medical experts discuss innovations and future directions in treatments for higher-risk MDS.

Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.

Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.

Medical experts discuss the data gathered from the ASCERTAIN trial.

Medical experts offer insights on the COMMANDS trial findings.

Medical experts discuss risk-based approaches to choosing MDS therapies.

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.

Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.

Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.

Experts consider shortcomings in the identification and management of myelodysplastic syndromes.

Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.

Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.

Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.

A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications.